🚀 VC round data is live in beta, check it out!
C4 Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for C4 Therapeutics and similar public comparables like Dishman Carbogen Amics, Alector, Lavipharm, Antibiotice and more.
C4 Therapeutics Overview
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Founded
2015
HQ
Employees
110
Website
Financials (LTM)
EV
$97M
C4 Therapeutics Financials
C4 Therapeutics reported last 12-month revenue of $32M.
In the same LTM period, C4 Therapeutics generated $28M in gross profit and had net loss of ($115M).
Revenue (LTM)
C4 Therapeutics P&L
In the most recent fiscal year, C4 Therapeutics reported revenue of $36M and EBITDA of ($103M).
C4 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $32M | XXX | $36M | XXX | XXX | XXX |
| Gross Profit | $28M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($103M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (285%) | XXX | XXX | XXX |
| EBIT Margin | (396%) | XXX | (291%) | XXX | XXX | XXX |
| Net Profit | ($115M) | XXX | ($105M) | XXX | XXX | XXX |
| Net Margin | (362%) | XXX | (292%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
C4 Therapeutics Stock Performance
C4 Therapeutics has current market cap of $285M, and enterprise value of $97M.
Market Cap Evolution
C4 Therapeutics' stock price is $2.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $97M | $285M | 0.0% | XXX | XXX | XXX | $-1.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialC4 Therapeutics Valuation Multiples
C4 Therapeutics trades at 3.1x EV/Revenue multiple, and (0.9x) EV/EBITDA.
EV / Revenue (LTM)
C4 Therapeutics Financial Valuation Multiples
As of April 19, 2026, C4 Therapeutics has market cap of $285M and EV of $97M.
Equity research analysts estimate C4 Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
C4 Therapeutics has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $285M | XXX | $285M | XXX | XXX | XXX |
| EV (current) | $97M | XXX | $97M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.9x) | XXX | XXX | XXX |
| EV/EBIT | (0.8x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | — | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified C4 Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
C4 Therapeutics Margins & Growth Rates
C4 Therapeutics' revenue in the last 12 month declined by (34%).
C4 Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.3M for the same period.
C4 Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (34%) | XXX | (40%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (285%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (1%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 121% | XXX | 101% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 352% | XXX | 290% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 391% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
C4 Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alector | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaryx Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
C4 Therapeutics M&A Activity
C4 Therapeutics acquired XXX companies to date.
Last acquisition by C4 Therapeutics was on XXXXXXXX, XXXXX. C4 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by C4 Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialC4 Therapeutics Investment Activity
C4 Therapeutics invested in XXX companies to date.
C4 Therapeutics made its latest investment on XXXXXXXX, XXXXX. C4 Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by C4 Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout C4 Therapeutics
| When was C4 Therapeutics founded? | C4 Therapeutics was founded in 2015. |
| Where is C4 Therapeutics headquartered? | C4 Therapeutics is headquartered in United States. |
| How many employees does C4 Therapeutics have? | As of today, C4 Therapeutics has over 110 employees. |
| Who is the CEO of C4 Therapeutics? | C4 Therapeutics' CEO is Andrew J. Hirsch. |
| Is C4 Therapeutics publicly listed? | Yes, C4 Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of C4 Therapeutics? | C4 Therapeutics trades under CCCC ticker. |
| When did C4 Therapeutics go public? | C4 Therapeutics went public in 2020. |
| Who are competitors of C4 Therapeutics? | C4 Therapeutics main competitors are Dishman Carbogen Amics, Alector, Lavipharm, Antibiotice. |
| What is the current market cap of C4 Therapeutics? | C4 Therapeutics' current market cap is $285M. |
| What is the current revenue of C4 Therapeutics? | C4 Therapeutics' last 12 months revenue is $32M. |
| What is the current revenue growth of C4 Therapeutics? | C4 Therapeutics revenue growth (NTM/LTM) is (34%). |
| What is the current EV/Revenue multiple of C4 Therapeutics? | Current revenue multiple of C4 Therapeutics is 3.1x. |
| Is C4 Therapeutics profitable? | No, C4 Therapeutics is not profitable. |
| What is the current net income of C4 Therapeutics? | C4 Therapeutics' last 12 months net income is ($115M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.